page contents March 2020 News Update

©2019 Anne Loeser  The Insider's Guide to Metastatic Breast Cancer  All rights reserved

The Insider's Guide to Metastatic Breast Cancer

A Summary of the Disease and its Treatments

by Anne Loeser

Woman Bench Dog.JPG
 
 
Search
  • Anne

March 2020 News Update

Updated: Mar 7


IIn Feb. 2020, the FDA approved the combination of Nerlynx (Neratinib) and Xeloda (capecitabine) for HER2-positive MBC patients who have received two or more prior anti-HER2 based regimens in the metastatic setting. Approval was based upon results from the Phase 3 NALA trial which showed that the combination of Nerlynx and Xeloda reduced the risk of disease progression or death by 24% compared with lapatinib (Tykerb) plus Xeloda. In the trial of 621 HER2+ MBC patients who were randomized to either Nerlynx + Xeloda or Tykerb + Xeloda, the 12-month Progression Free Survival rates were 29% for the Nerlynx combination vs. 15%, for the Tykerb combination, and the 24-month PFS rates were 12% and 3%, respectively. Moreover, the median Overall Survival was 21 months for patients on the Nerlynx combination vs. 18.7 months for patients on the Tykerb combination. From: https://www.onclive.com/web-exclusives/fda-approves-neratinib-combo-for-her2-breast-cancer?utm_medium=email&utm_campaign=ONC+Breaking+News+2-26-20&utm_content=ONC+Breaking+News+2-26-20+CID_00e83ce7705b5e1d314f8139dcf0d0fb&utm_source=CM+ONCLIVE&utm_term=READ+MORE&fbclid=IwAR1ZLfCgiHnEqbrA4w0N83XRetyMwXZGixu3BfMrs1JO5CoiUIWiIkVbKJA



376 views